Home › Esophageal Adenocarcinoma › Pennsylvania › Harrisburg
Esophageal Adenocarcinoma clinical trials in Harrisburg, PA
3 studies for Esophageal Adenocarcinoma are looking for participants at sites in and around Harrisburg (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
RecruitingPhase 2/3
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus, Harrisburg
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion, Mechanicsburg · 8 mi away
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RecruitingPhase 1/2
- Penn State Milton S. Hershey Medical Center, Hershey · 12 mi away
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RecruitingPhase 3
- Research Site, Hershey · 12 mi away
Esophageal Adenocarcinoma trials in other cities
- New York City, NY18 studies
- Boston, MA13 studies
- Houston, TX12 studies
- Arlington, VA11 studies
- Nashville, TN11 studies
- Durham, NC10 studies
- St. Louis, MO9 studies
- Rochester, MN9 studies
- Jacksonville, FL9 studies
- Baldwin Park, CA9 studies
- Queens, NY9 studies
- Los Angeles, CA9 studies
Other studies in Harrisburg
- Heart Failure14 studies
- Breast Cancer12 studies
- Non-Small Cell Lung Cancer12 studies
- Cardiovascular Disease11 studies
- Lung Cancer9 studies
- Acute Myeloid Leukemia8 studies
- Prostate Cancer8 studies
- Colorectal Cancer7 studies
- Head and Neck Squamous Cell Carcinoma7 studies
- Neuroblastoma6 studies
- Crohn's Disease6 studies
- High Blood Pressure6 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.